Close

Audentes Therapeutics (BOLD) Announces Continuing Positive Data from First Dose Cohort of ASPIRO

May 16, 2018 11:30 AM EDT Send to a Friend
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login